Cardiovascular events · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · Adults without diabetes or CVD
1 finding from 1 review
Cholesterol mg/dL · Adults without diabetes or CVD
1 finding from 1 review
LDL‐cholesterol · Adults without diabetes or CVD
1 finding from 1 review
HDL‐cholesterol · Adults without diabetes or CVD
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults without diabetes or CVD
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes side effects (tachycardia, agitation or feed intolerance) leading to… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
1 finding from 1 review
Side effects · women with pre‐eclampsia
Prevention of eclampsia: higher showed no clear difference in side effects compared with lower IV maintenance regimen (low certainty).
1 finding from 1 review
HDL‐cholesterol · Participants with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects (loose stools, diarrhoea) · Infants (primary teeth; baseline about 9 to 15 months)
1 finding from 1 review
Adverse effects were not reported in a usable format, but the reported rates of loose stools and diarrhoea were very similar between groups. There were no serious adverse effects during the study. Milgrom 2009.
1 study · 94 participants
GRADE not reported
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in withdrawals due to adverse effects compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with low dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review